Ancora Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Ancora Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,479	Closed	-$13K	–	687
2017 Q2	$13K	Hold	1,479	–	–	﹤0.01%	624
2017 Q1	$39K	Hold	1,479	–	–	﹤0.01%	615
2016 Q4	$65K	Sell	1,479 -1,100	-43%	-$35.1K	﹤0.01%	735
2016 Q3	$41K	Hold	2,579	–	–	﹤0.01%	521
2016 Q2	$85K	Hold	2,579	–	–	0.01%	499
2016 Q1	$72K	Hold	2,579	–	–	0.01%	481
2015 Q4	$120K	Sell	2,579 -450	-15%	-$50.1K	0.02%	470
2015 Q3	$542K	Hold	3,029	–	–	0.07%	291
2015 Q2	$433K	Buy	+3,029	New	+$420K	0.05%	344
2015 Q1	–	Sell	-1,550	Closed	-$254K	–	382
2014 Q4	$277K	Buy	+1,550	New	+$276K	0.03%	406

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Ancora Advisors's IDXG Position: Q3 2017 in Review

Ancora Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2017, closing a stake of 1,479 shares — an estimated $13K sold.

Ancora Advisors first reported a position in IDXG in Q4 2014 and held it in 10 quarters. The position peaked at $542K in Q3 2015. 13 funds tracked by Wall St. Rank hold IDXG as of Q3 2017.

Ancora Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Ancora Advisors sold 1,479 Interpace Biosciences, Inc. Common Stock shares in Q3 2017, an estimated $13K.
Ancora Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
Ancora Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $542K in Q3 2015.
13 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2017.

Based on Ancora Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.